Subcommittee on the Control of Anticoagulation: Assessment of effectiveness of major bleeding management; Proposed definitions for effective hemostasis
A broad spectrum of definitions for the clinical effectiveness of management given for bleeding events related to anticoagulants have been used in published clinical studies [1-3]. This diversity hampers any attempt to compare the different trials and to perform meta-analyses . Yet, without doubt, clinical outcome in the form of hemostatic efficacy is the most important parameter for evaluating the effectiveness of a given therapy. Read more.
Subcommittee on the Control of Anticoagulation: Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients The term clinically relevant non-major bleeding (CRNMB) has recently been incorporated into the outcomes of atrial fibrillation (AF) and venous thromboembolic (VTE) disease clinical trials to further define a bleeding event that is neither a major bleed as defined by the International Society on Thrombosis and Haemostasis (ISTH), nor a non-clinically consequential minor bleeding event. This relatively new term for anticoagulant related bleeding suffers the same lack of harmonization as major bleeding did a decade ago. Read more.